HNGE Stock Analysis: Hinge Health | NYSE
Health Information Services | NYSE, USA | Market Cap: 9.378m USD | 12M Return: 197% | US4333131039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 212M
Qual. Beats: 2
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.5 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Hinge Health, Inc. (NYSE: HNGE) is a digital health company founded in 2012 and headquartered in San Francisco, California, that uses technology to scale the delivery of musculoskeletal (MSK) care. Its platform addresses acute injuries, chronic pain, and post-surgical rehabilitation through AI-powered motion tracking and a proprietary electrical nerve stimulation wearable device. The company primarily sells to self-insured employers, aligning with the broader digital health and virtual care model in which MSK conditions represent a significant share of employer health plan spend. Hinge Health went public on May 22, 2025, and is classified within the Health Care sector under the Health Care Services sub-industry, with a mid-cap market capitalization of approximately $7.9 billion.
- Self-insured employer contracts drive member enrollment growth
- AI motion tracking widens lead versus Sword Health
- GLP-1 drugs could reduce musculoskeletal surgery volumes
| Net Income: 168.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.36 > 0.02 and ΔFCF/TA 18.12 > 1.0 |
| NWC/Revenue: 2.89% < 20% (prev 56.48%; Δ -53.59% < -1%) |
| CFO/TA 0.37 > 3% & CFO 323.0m > Net Income 168.3m |
| Net Debt (-260.8m) to EBITDA (164.4m): -1.59 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.5m) vs 12m ago 9.72% < -2% |
| Gross Margin: 85.75% > 18% (prev 78.65%; Δ 7.09% > 0.5%) |
| Asset Turnover: 97.43% > 50% (prev 69.42%; Δ 28.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.03 (Total Current Assets 567.9m - Total Current Liabilities 544.7m) / Total Assets 874.1m |
| B: -1.05 (Retained Earnings -914.8m / Total Assets 874.1m) |
| C: 0.19 (EBIT TTM 158.7m / Avg Total Assets 821.9m) |
| D: 0.52 (Book Value of Equity 299.4m / Total Liabilities 574.7m) |
| Altman-Z'' = -1.39 = CCC |
| DSRI: 1.14 (Receivables 148.5m/86.8m, Revenue 800.8m/534.4m) |
| GMI: 0.92 (GM 78.65% / 85.75%) |
| AQI: 2.41 (AQ_t 0.30 / AQ_t-1 0.12) |
| SGI: 1.50 (Revenue 800.8m / 534.4m) |
| TATA: -0.18 (NI 168.3m - CFO 323.0m) / TA 874.1m) |
| Beneish M = -1.81 (Cap -4..+1) = B |
As of November 17, 2026, the stock is trading at USD 121.29 with a total of 2,079,626 shares traded. Over the past week, the price has changed by -0.74%, over one month by +22.32%, over three months by +38.03% and over the past year by +196.99%.
Current recommended Stop Loss: 114.70 (which is 5.4% or 1.2 ATR below the current price).
Hinge Health has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy HNGE.
- StrongBuy: 9
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 135.4 | 11.6% |
P/E Trailing = 31.271
P/E Forward = 37.4532
P/S = 11.7104
P/B = 31.3204
Revenue TTM = 800.8m USD
EBIT TTM = 158.7m USD
EBITDA TTM = 164.4m USD
Long Term Debt = 29.2m USD (estimated: total debt 33.9m - short term 4.72m)
Short Term Debt = 4.72m USD (from shortTermDebt, last quarter)
Debt = 33.9m USD (from shortLongTermDebtTotal, last quarter) (leases 33.9m already included)
Net Debt = -260.8m USD (calculated: Debt 33.9m - CCE 294.7m)
Enterprise Value = 9.12b USD (9.38b + Debt 33.9m - CCE 294.7m)
Interest Coverage Ratio = unknown (Ebit TTM 158.7m / Interest Expense TTM 0.0)
EV/FCF = 28.61x (Enterprise Value 9.12b / FCF TTM 318.7m)
FCF Yield = 3.50% (FCF TTM 318.7m / Enterprise Value 9.12b)
FCF Margin = 39.80% (FCF TTM 318.7m / Revenue TTM 800.8m)
Net Margin = 21.02% (Net Income TTM 168.3m / Revenue TTM 800.8m)
Gross Margin = 85.75% ((Revenue TTM 800.8m - Cost of Revenue TTM 114.1m) / Revenue TTM)
Gross Margin QoQ = 86.96% (prev 86.44%)
Tobins Q-Ratio = 10.43 (Enterprise Value 9.12b / Total Assets 874.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 33.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 125.4m (EBIT 158.7m * (1 - 21.00%))
Current Ratio = 1.04 (Total Current Assets 567.9m / Total Current Liabilities 544.7m)
Debt / Equity = 0.11 (Debt 33.9m / totalStockholderEquity, last quarter 299.4m)
Debt / EBITDA = -1.59 (Net Debt -260.8m / EBITDA 164.4m)
Debt / FCF = -0.82 (Net Debt -260.8m / FCF TTM 318.7m)
Total Stockholder Equity = 333.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.48% (Net Income 168.3m / Total Assets 874.1m)
RoE = 50.47% (Net Income TTM 168.3m / Total Stockholder Equity 333.5m)
RoCE = 43.76% (EBIT 158.7m / Capital Employed (Equity 333.5m + L.T.Debt 29.2m))
RoIC = 42.63% (NOPAT 125.4m / Invested Capital 294.1m)
WACC = 8.99% (E(9.38b)/V(9.41b) * Re(9.02%) + D(33.9m)/V(9.41b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 9.45 | Cagr: -2.64%
[DCF] Terminal Value 75.93% ; FCFF base≈247.7m ; Y1≈283.9m ; Y5≈417.9m
[DCF] Fair Price = 86.37 (EV 5.65b - Net Debt -260.8m = Equity 5.92b / Shares 68.5m; r=8.99% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.10 | # QB: 2
Revenue Correlation: 99.50 | Revenue CAGR: 41.71% | SUE: 0.36 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.64 | Chg30d=+6.04% | Revisions=+42% | Analysts=12
EPS current Year (2026-12-31): EPS=2.57 | Chg30d=+7.23% | Revisions=+69% | GrowthEPS=-1.8% | GrowthRev=+49.4%
EPS next Year (2027-12-31): EPS=3.26 | Chg30d=+6.49% | Revisions=+67% | GrowthEPS=+26.6% | GrowthRev=+27.0%
[Analyst] Revisions Ratio: +70% (up=30, down=4)